Treatment options for people with acute myeloid leukemia (AML) have expanded. On July 20, the Food and Drug Administration (FDA) approved quizartinib (Vanflyta) combined with chemotherapy as a first-line treatment for AML with a specific change in the FLT3 gene. The approval was based on results from a large clinical trial called QuANTUM-First.
Treating the rare brain tumor craniopharyngioma often requires surgery, radiation therapy, or both. But results of a recent clinical trial suggest that, for many, combining the targeted therapies vemurafenib (Zelboraf) and cobimetinib (Cotellic) may delay, or even eliminate, the need for these treatments.
FDA approved enzalutamide (Xtandi) combined with talazoparib (Talzenna) for certain metastatic prostate cancers with changes in any of 12 genes involved in repairing broken DNA. The drug combination was more effective than the standard treatment in a large clinical trial.
Clinical Trials Information for Patients and Caregivers
Designing and running a clinical trial requires the skills of many different types of experts. This page describes the typical team members involved in a clinical trial and their responsibilities.
This phase 3 trial will test the immunotherapy drug pembrolizumab (Keytruda) combined with chemotherapy compared with chemotherapy alone for people with early-stage non-small cell lung cancer that has been surgically removed. This study, part of the ALCHEMIST lung cancer trials, will help determine if adding pembrolizumab to chemotherapy helps prevent the cancer from coming back.
This phase 2 trial will test the targeted drugs selumetinib (Koselugo) and olaparib (Lynparza) compared with selumetinib alone in people with advanced endometrial or ovarian cancer. The drugs target different mutated proteins that are often found in these cancers. Doctors want to see which treatment works better to shrink or prevent tumors from growing. This trial is part of the ComboMATCH studies.
In this phase 3 trial, people who have had one or two small benign polyps removed during a routine screening colonoscopy will be assigned by chance to have their next colonoscopy at 5 or 10 years. The findings from the trial, called FORTE, will help determine if people who have had up to two small polyps removed during a routine colonoscopy can wait 10 years for another one.
